Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 330

1.

Interleukin-6 inhibits receptor activator of nuclear factor kappaB ligand-induced osteoclastogenesis by diverting cells into the macrophage lineage: key role of Serine727 phosphorylation of signal transducer and activator of transcription 3.

Duplomb L, Baud'huin M, Charrier C, Berreur M, Trichet V, Blanchard F, Heymann D.

Endocrinology. 2008 Jul;149(7):3688-97. doi: 10.1210/en.2007-1719. Epub 2008 Apr 10.

PMID:
18403479
2.

Cysteine proteinase inhibitors regulate human and mouse osteoclastogenesis by interfering with RANK signaling.

Strålberg F, Henning P, Gjertsson I, Kindlund B, Souza PP, Persson E, Abrahamson M, Kasprzykowski F, Grubb A, Lerner UH.

FASEB J. 2013 Jul;27(7):2687-701. doi: 10.1096/fj.12-211748. Epub 2013 Apr 9.

PMID:
23572233
3.

BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.

Valverde P, Tu Q, Chen J.

J Bone Miner Res. 2005 Sep;20(9):1669-79. Epub 2005 May 16.

4.

Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells.

Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H, Miyahara T.

Bone. 2007 Oct;41(4):592-602. Epub 2007 Jun 13.

PMID:
17627913
6.

The 4-1BB ligand and 4-1BB expressed on osteoclast precursors enhance RANKL-induced osteoclastogenesis via bi-directional signaling.

Yang J, Park OJ, Lee YJ, Jung HM, Woo KM, Choi Y.

Eur J Immunol. 2008 Jun;38(6):1598-609. doi: 10.1002/eji.200737650.

7.

Molecular basis of requirement of receptor activator of nuclear factor κB signaling for interleukin 1-mediated osteoclastogenesis.

Jules J, Zhang P, Ashley JW, Wei S, Shi Z, Liu J, Michalek SM, Feng X.

J Biol Chem. 2012 May 4;287(19):15728-38. doi: 10.1074/jbc.M111.296228. Epub 2012 Mar 13.

8.

Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.

Kim MH, Ryu SY, Choi JS, Min YK, Kim SH.

J Cell Physiol. 2009 Dec;221(3):618-28. doi: 10.1002/jcp.21892.

PMID:
19653230
10.

Interleukin-4 inhibits RANKL-induced expression of NFATc1 and c-Fos: a possible mechanism for downregulation of osteoclastogenesis.

Kamel Mohamed SG, Sugiyama E, Shinoda K, Hounoki H, Taki H, Maruyama M, Miyahara T, Kobayashi M.

Biochem Biophys Res Commun. 2005 Apr 15;329(3):839-45.

PMID:
15752732
11.

AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis.

Li CH, Zhao JX, Sun L, Yao ZQ, Deng XL, Liu R, Liu XY.

Biochem Biophys Res Commun. 2013 Jun 14;435(4):533-9. doi: 10.1016/j.bbrc.2013.04.084. Epub 2013 May 7.

PMID:
23665018
13.

Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling.

Kalliolias GD, Zhao B, Triantafyllopoulou A, Park-Min KH, Ivashkiv LB.

Arthritis Rheum. 2010 Feb;62(2):402-13. doi: 10.1002/art.27200.

14.

Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.

Gong W, Dou H, Liu X, Sun L, Hou Y.

Clin Exp Pharmacol Physiol. 2012 Oct;39(10):886-93. doi: 10.1111/j.1440-1681.2012.12006.x.

PMID:
23013134
15.

Maslinic acid suppresses osteoclastogenesis and prevents ovariectomy-induced bone loss by regulating RANKL-mediated NF-κB and MAPK signaling pathways.

Li C, Yang Z, Li Z, Ma Y, Zhang L, Zheng C, Qiu W, Wu X, Wang X, Li H, Tang J, Qian M, Li D, Wang P, Luo J, Liu M.

J Bone Miner Res. 2011 Mar;26(3):644-56. doi: 10.1002/jbmr.242.

16.

Inhibition of receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclast formation by pyrroloquinoline quinine (PQQ).

Odkhuu E, Koide N, Haque A, Tsolmongyn B, Naiki Y, Hashimoto S, Komatsu T, Yoshida T, Yokochi T.

Immunol Lett. 2012 Feb 29;142(1-2):34-40. doi: 10.1016/j.imlet.2011.12.001. Epub 2011 Dec 13.

PMID:
22193059
17.

Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.

Fujisaki K, Tanabe N, Suzuki N, Kawato T, Takeichi O, Tsuzukibashi O, Makimura M, Ito K, Maeno M.

Life Sci. 2007 Mar 13;80(14):1311-8. Epub 2007 Jan 23.

PMID:
17306833
18.

Methylsulfonylmethane Inhibits RANKL-Induced Osteoclastogenesis in BMMs by Suppressing NF-κB and STAT3 Activities.

Joung YH, Darvin P, Kang DY, Sp N, Byun HJ, Lee CH, Lee HK, Yang YM.

PLoS One. 2016 Jul 22;11(7):e0159891. doi: 10.1371/journal.pone.0159891. eCollection 2016.

19.

Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis.

Kimachi K, Kajiya H, Nakayama S, Ikebe T, Okabe K.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Mar;383(3):297-308. doi: 10.1007/s00210-010-0596-4. Epub 2011 Jan 12.

PMID:
21225243
20.

Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.

Takatsuna H, Asagiri M, Kubota T, Oka K, Osada T, Sugiyama C, Saito H, Aoki K, Ohya K, Takayanagi H, Umezawa K.

J Bone Miner Res. 2005 Apr;20(4):653-62. Epub 2004 Dec 6.

Supplemental Content

Support Center